
‘Pharma Bro’ Martin Shkreli wins proxy battle from prison
NY Post
A group of activist investors seeking to wrest control of Martin Shkreli’s pharmaceutical company failed miserably this week — with the “Pharma Bro” voting his shares from prison.
But the battle is not over, and the investors now plan to seize Shkreli’s 44 percent stake in Phoenixus – the parent of Shkreli’s Turing Pharmaceuticals, now renamed Vyera, The Post has learned. On Monday, former Shkreli confidante and Vyera executive Kevin Mulleady, together with Jason Aryeh, a longtime activist investor in the pharmaceutical industry, held a special meeting asking Phoenixus shareholders to replace the current board of directors, who they say are Shkreli cronies.More Related News

Gas prices reach highest level since October 2023 as oil holds above $100 per barrel; US stocks jump
Brent crude oil held above $100 per barrel on Monday, pushing national average gasoline prices to their highest level since October 2023 as President Trump urged allies to help protect oil tankers from Iranian attacks in the key Strait of Hormuz.












